Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications

Helen C. Kales, Marcia Valenstein, H. Myra Kim, John F. McCarthy, Dara Ganoczy, Francesca Cunningham, Frederic C. Blow

Research output: Contribution to journalArticle

180 Citations (Scopus)

Abstract

Objective: Mortality rates in the year following new antipsychotic medication starts for neuropsychiatric symptoms of dementia were compared with rates after starts of other psychiatric medications. Method: The retrospective, cohort study used national data from the Department of Veterans Affairs (fiscal years 2001-2005) on patients older than 65 years who began outpatient treatment with psychiatric medication following a dementia diagnosis (N=10,615). Twelve-month mortality rates were compared in patients taking antipsychotics and those taking other psychiatric medications. The authors controlled for confounding by using multivariate models and propensity-scoring methods. Secondary analyses included a no-medication group and examination of mortality causes. Results: All groups taking antipsychotics had significantly higher mortality rates (22.6%-29.1%) than patients taking nonantipsychotic medications (14.6%). Adjusted mortality risks for atypicals and for combined atypical and conventional antipsychotics were similar to those for conventional antipsychotics. The mortality risk was significantly lower for nonantipsychotic medications than conventional antipsychotics. Except for anticonvulsants, the adjusted risks for all individual classes of nonantipsychotics were significantly lower than the risk for antipsychotics. Mortality risks did not change over 12 months. The proportions of patients taking antipsychotics who died from cerebrovascular, cardiovascular, or infectious causes were not higher than rates for those taking nonantipsychotic psychiatric medications. Conclusions: Antipsychotic medications taken by patients with dementia were associated with higher mortality rates than were most other medications used for neuropsychiatric symptoms. The association between mortality and antipsychotics is not well understood and may be due to a direct medication effect or the pathophysiology underlying neuropsychiatric symptoms that prompt antipsychotic use.

Original languageEnglish (US)
Pages (from-to)1568-1576
Number of pages9
JournalAmerican Journal of Psychiatry
Volume164
Issue number10
DOIs
StatePublished - Oct 1 2007
Externally publishedYes

Fingerprint

Antipsychotic Agents
Psychiatry
Dementia
Mortality
Veterans
Anticonvulsants
Cohort Studies
Research Design
Outpatients
Retrospective Studies

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. / Kales, Helen C.; Valenstein, Marcia; Kim, H. Myra; McCarthy, John F.; Ganoczy, Dara; Cunningham, Francesca; Blow, Frederic C.

In: American Journal of Psychiatry, Vol. 164, No. 10, 01.10.2007, p. 1568-1576.

Research output: Contribution to journalArticle

Kales, Helen C. ; Valenstein, Marcia ; Kim, H. Myra ; McCarthy, John F. ; Ganoczy, Dara ; Cunningham, Francesca ; Blow, Frederic C. / Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. In: American Journal of Psychiatry. 2007 ; Vol. 164, No. 10. pp. 1568-1576.
@article{458beae0f3044f38b09f7c41711cdc23,
title = "Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications",
abstract = "Objective: Mortality rates in the year following new antipsychotic medication starts for neuropsychiatric symptoms of dementia were compared with rates after starts of other psychiatric medications. Method: The retrospective, cohort study used national data from the Department of Veterans Affairs (fiscal years 2001-2005) on patients older than 65 years who began outpatient treatment with psychiatric medication following a dementia diagnosis (N=10,615). Twelve-month mortality rates were compared in patients taking antipsychotics and those taking other psychiatric medications. The authors controlled for confounding by using multivariate models and propensity-scoring methods. Secondary analyses included a no-medication group and examination of mortality causes. Results: All groups taking antipsychotics had significantly higher mortality rates (22.6{\%}-29.1{\%}) than patients taking nonantipsychotic medications (14.6{\%}). Adjusted mortality risks for atypicals and for combined atypical and conventional antipsychotics were similar to those for conventional antipsychotics. The mortality risk was significantly lower for nonantipsychotic medications than conventional antipsychotics. Except for anticonvulsants, the adjusted risks for all individual classes of nonantipsychotics were significantly lower than the risk for antipsychotics. Mortality risks did not change over 12 months. The proportions of patients taking antipsychotics who died from cerebrovascular, cardiovascular, or infectious causes were not higher than rates for those taking nonantipsychotic psychiatric medications. Conclusions: Antipsychotic medications taken by patients with dementia were associated with higher mortality rates than were most other medications used for neuropsychiatric symptoms. The association between mortality and antipsychotics is not well understood and may be due to a direct medication effect or the pathophysiology underlying neuropsychiatric symptoms that prompt antipsychotic use.",
author = "Kales, {Helen C.} and Marcia Valenstein and Kim, {H. Myra} and McCarthy, {John F.} and Dara Ganoczy and Francesca Cunningham and Blow, {Frederic C.}",
year = "2007",
month = "10",
day = "1",
doi = "10.1176/appi.ajp.2007.06101710",
language = "English (US)",
volume = "164",
pages = "1568--1576",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "10",

}

TY - JOUR

T1 - Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications

AU - Kales, Helen C.

AU - Valenstein, Marcia

AU - Kim, H. Myra

AU - McCarthy, John F.

AU - Ganoczy, Dara

AU - Cunningham, Francesca

AU - Blow, Frederic C.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Objective: Mortality rates in the year following new antipsychotic medication starts for neuropsychiatric symptoms of dementia were compared with rates after starts of other psychiatric medications. Method: The retrospective, cohort study used national data from the Department of Veterans Affairs (fiscal years 2001-2005) on patients older than 65 years who began outpatient treatment with psychiatric medication following a dementia diagnosis (N=10,615). Twelve-month mortality rates were compared in patients taking antipsychotics and those taking other psychiatric medications. The authors controlled for confounding by using multivariate models and propensity-scoring methods. Secondary analyses included a no-medication group and examination of mortality causes. Results: All groups taking antipsychotics had significantly higher mortality rates (22.6%-29.1%) than patients taking nonantipsychotic medications (14.6%). Adjusted mortality risks for atypicals and for combined atypical and conventional antipsychotics were similar to those for conventional antipsychotics. The mortality risk was significantly lower for nonantipsychotic medications than conventional antipsychotics. Except for anticonvulsants, the adjusted risks for all individual classes of nonantipsychotics were significantly lower than the risk for antipsychotics. Mortality risks did not change over 12 months. The proportions of patients taking antipsychotics who died from cerebrovascular, cardiovascular, or infectious causes were not higher than rates for those taking nonantipsychotic psychiatric medications. Conclusions: Antipsychotic medications taken by patients with dementia were associated with higher mortality rates than were most other medications used for neuropsychiatric symptoms. The association between mortality and antipsychotics is not well understood and may be due to a direct medication effect or the pathophysiology underlying neuropsychiatric symptoms that prompt antipsychotic use.

AB - Objective: Mortality rates in the year following new antipsychotic medication starts for neuropsychiatric symptoms of dementia were compared with rates after starts of other psychiatric medications. Method: The retrospective, cohort study used national data from the Department of Veterans Affairs (fiscal years 2001-2005) on patients older than 65 years who began outpatient treatment with psychiatric medication following a dementia diagnosis (N=10,615). Twelve-month mortality rates were compared in patients taking antipsychotics and those taking other psychiatric medications. The authors controlled for confounding by using multivariate models and propensity-scoring methods. Secondary analyses included a no-medication group and examination of mortality causes. Results: All groups taking antipsychotics had significantly higher mortality rates (22.6%-29.1%) than patients taking nonantipsychotic medications (14.6%). Adjusted mortality risks for atypicals and for combined atypical and conventional antipsychotics were similar to those for conventional antipsychotics. The mortality risk was significantly lower for nonantipsychotic medications than conventional antipsychotics. Except for anticonvulsants, the adjusted risks for all individual classes of nonantipsychotics were significantly lower than the risk for antipsychotics. Mortality risks did not change over 12 months. The proportions of patients taking antipsychotics who died from cerebrovascular, cardiovascular, or infectious causes were not higher than rates for those taking nonantipsychotic psychiatric medications. Conclusions: Antipsychotic medications taken by patients with dementia were associated with higher mortality rates than were most other medications used for neuropsychiatric symptoms. The association between mortality and antipsychotics is not well understood and may be due to a direct medication effect or the pathophysiology underlying neuropsychiatric symptoms that prompt antipsychotic use.

UR - http://www.scopus.com/inward/record.url?scp=35748963236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748963236&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2007.06101710

DO - 10.1176/appi.ajp.2007.06101710

M3 - Article

C2 - 17898349

AN - SCOPUS:35748963236

VL - 164

SP - 1568

EP - 1576

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 10

ER -